METHYL NICOTINATE
Psychotic Disorders
Nova Scotia Health AuthoritySmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Psychotic Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olanzapine Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Risperdal Northwell Health | Phase 4 | BBB |
Paliperidone Palmitate 3-Month Formulation Consorcio Centro de Investigación Biomédica en Red (CIBER) | Phase 4 | BBB |
Sertraline Northwell Health | Phase 4 | BBB |
Cipralex Northwell Health | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
METHYL NICOTINATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →